CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Inlyta for metastatic renal cell carcinoma (mRCC) - Details

Note: The pCODR Provincial Advisory Group, PAG, has submitted a Request for Advice for this drug & indication on April 18, 2017. Please see the RFA: Inlyta for Metastatic Renal Cell Carcinoma details page for more information:

Project Number PC0013-000
Brand Name Inlyta
Generic Name Axitinib
Strength 1mg and 5mg
Tumour Type Genitourinary
Indication Metastatic Renal Cell Carcinoma
Funding Request For the treatment of patients with metastatic renal cell carcinoma (RCC) of clear histology after failure of prior systemic therapy with either a cytokine or the VEGFR-TKI, sunitinib
Review Status Complete
Pre Noc Submission No
NOC Date July 12, 2012
Manufacturer Pfizer Canada Inc.
Sponsor Pfizer Canada Inc.
Submission Date August 16, 2012
Submission Deemed Complete August 23, 2012
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ August 30, 2012
Check-point meeting October 10, 2012
pERC Meeting December 20, 2012
Initial Recommendation Issued January 14, 2013
Feedback Deadline ‡ January 28, 2013
pERC Reconsideration Meeting February 21, 2013
Final Recommendation Issued March 7, 2013
Notification to Implement Issued March 22, 2013
Therapeutic Area Metastatic Renal Cell Carcinoma
Recommendation Type Reimburse

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.